Print
19 June 2018
GMP News
An official ceremony marking the launch of construction was held at the site of future plant for active pharmaceutical substances and finished medicinal products of Pharmasyntez-Chemie in Usolye-Sibirskoye on June 15.
The plans provide for construction of several plants in Usolye-Sibirskoye, including facilities for manufacturing active pharmaceutical substances, finished medicinal products, and solvent recovery. These facilities will be combined into a pharmaceutical industrial technopark, which will have an administrative office building, research center with several laboratories featuring the most modern equipment for implementing new projects to develop and manufacture original medicines, and pilot plants to elaborate manufacturing technology for new products. The plans also provide for utilities, transport, and technological infrastructure, which will be used by the residents of technopark, and recreation sites for employees. Preliminary amount of investments is estimated at 10 billion rubles, and the number of new jobs will be 2000.
“Today is a historic day. Here, we will create the largest infrastructure in the world to manufacture the pharmaceuticals. I very much hope that we will launch production by 2021 and, by 2025, our output will exceed the figures achieved at the best times of the Soviet Union, when Usolye-Sibirskoye was manufacturing antibiotics for one fifth of the world’s population. We understand that Pharmasyntez, like any other company, will not implement such project alone,” said Vikram Punia, President of Pharmasyntez Group.
The RMI group has completed sertain projects
The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.